• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review.基于 NNRTI 的治疗方案用于 HIV 感染成人临床试验中使用的患者报告结局指标:十年回顾。
Health Qual Life Outcomes. 2013 Oct 3;11:164. doi: 10.1186/1477-7525-11-164.
2
Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden.
AIDS Care. 2014 Apr;26(4):466-75. doi: 10.1080/09540121.2013.841825. Epub 2013 Oct 10.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.与非核苷类逆转录酶抑制剂耐药相关的突变的汇编与流行情况
Antivir Ther. 2009;14(1):103-9.
5
Prevalence and outcomes of recycling NNRTIs despite documented NNRTI resistance in HIV-infected children and youth.尽管有记录显示 HIV 感染儿童和青少年对 NNRTI 具有耐药性,但 NNRTI 再循环的流行率和结局。
AIDS Patient Care STDS. 2014 Jan;28(1):10-4. doi: 10.1089/apc.2013.0308.
6
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.在接受含非核苷类逆转录酶抑制剂(NNRTI)的初始三联疗法的患者中,NNRTI敏感性的适度降低不会影响病毒学结果。
Antivir Ther. 2003 Oct;8(5):395-402.
7
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.依非韦伦或奈韦拉平与两种核苷类或核苷酸类逆转录酶抑制剂联合用于初治抗逆转录病毒治疗的HIV感染者的初始治疗。
Cochrane Database Syst Rev. 2016 Dec 10;12(12):CD004246. doi: 10.1002/14651858.CD004246.pub4.
8
Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.依曲韦林:一种第二代非核苷类逆转录酶抑制剂(NNRTI),对耐 NNRTI 的 HIV 毒株具有活性。
Clin Ther. 2009 Apr;31(4):692-704. doi: 10.1016/j.clinthera.2009.04.020.
9
Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.初治HIV感染患者中非核苷类逆转录酶抑制剂(NNRTI)耐药相关突变及多态性的流行情况。
HIV Clin Trials. 2002 Jan-Feb;3(1):36-44. doi: 10.1310/5H0R-UDC8-8RR7-XEMJ.
10

引用本文的文献

1
Toward Reliable Symptom Coding in Electronic Health Records for Symptom Assessment and Research: Identification and Categorization of International Classification of Diseases, Ninth Revision, Clinical Modification Symptom Codes.迈向电子健康记录中可靠症状编码用于症状评估和研究:国际疾病分类,第九版,临床修正症状代码的识别和分类。
Comput Inform Nurs. 2024 Sep 1;42(9):636-647. doi: 10.1097/CIN.0000000000001146.
2
Clinical benefits of novel non-nucleoside reverse transcriptase inhibitors: A prospective cohort study.新型非核苷类逆转录酶抑制剂的临床获益:一项前瞻性队列研究。
Immun Inflamm Dis. 2024 Apr;12(4):e1217. doi: 10.1002/iid3.1217.
3
How quality of life is measured in studies of nutritional intervention: a systematic review.营养干预研究中生活质量的测量方法:系统评价。
Health Qual Life Outcomes. 2024 Jan 24;22(1):9. doi: 10.1186/s12955-024-02229-y.
4
Investigating coping and stigma in people living with HIV through narrative medicine in the Italian multicentre non-interventional study DIAMANTE.通过意大利多中心非干预性研究 DIAMANTE 中的叙事医学研究 HIV 感染者的应对和污名化。
Sci Rep. 2023 Oct 17;13(1):17624. doi: 10.1038/s41598-023-44768-2.
5
Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China.在中国西南部,接受比替拉韦/恩曲他滨/替诺福韦艾拉酚胺治疗的 HIV 感染者的临床疗效、安全性和基于 ePRO 的主观体验。
Immun Inflamm Dis. 2023 Aug;11(8):e974. doi: 10.1002/iid3.974.
6
HIV-Specific Reported Outcome Measures: Systematic Review of Psychometric Properties.HIV 特异性报告结局指标:心理计量学特性的系统评价。
JMIR Public Health Surveill. 2022 Dec 8;8(12):e39015. doi: 10.2196/39015.
7
Patient-Reported Outcomes (PROs) in HIV Infection: Points to Consider and Challenges.HIV感染中的患者报告结局(PROs):需考虑的要点与挑战
Infect Dis Ther. 2022 Oct;11(5):2017-2033. doi: 10.1007/s40121-022-00678-w. Epub 2022 Sep 6.
8
Understanding the Risks and Benefits of a Patient Portal Configured for HIV Care: Patient and Healthcare Professional Perspectives.了解为艾滋病护理配置的患者门户网站的风险与益处:患者及医疗保健专业人员的观点。
J Pers Med. 2022 Feb 19;12(2):314. doi: 10.3390/jpm12020314.
9
Quality of life among people living with HIV in England and the Netherlands: a population-based study.英国和荷兰艾滋病毒感染者的生活质量:一项基于人群的研究。
Lancet Reg Health Eur. 2021 Jul 19;8:100177. doi: 10.1016/j.lanepe.2021.100177. eCollection 2021 Sep.
10
Redefining therapeutic success in HIV patients: an expert view.重新定义 HIV 患者的治疗成功:专家观点。
J Antimicrob Chemother. 2021 Sep 15;76(10):2501-2518. doi: 10.1093/jac/dkab168.

本文引用的文献

1
Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.赛庚啶预防依非韦伦所致神经精神不良事件的随机临床试验
AIDS Patient Care STDS. 2013 Mar;27(3):146-54. doi: 10.1089/apc.2012.0410. Epub 2013 Feb 26.
2
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.在改用基于拉替拉韦方案的三联疗法经验丰富的患者中,基线因素无法预测一年时的病毒学失败情况。
Int J STD AIDS. 2012 Jul;23(7):459-63. doi: 10.1258/ijsa.2012.011391.
3
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.一项在脂肪营养不良的 HIV 感染妇女中用雷特格韦替代蛋白酶抑制剂或非核苷类逆转录酶抑制剂的随机试验。
AIDS Patient Care STDS. 2012 Sep;26(9):532-40. doi: 10.1089/apc.2012.0135. Epub 2012 Jul 23.
4
A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.南非未经治疗的 HIV 相关性卡波西肉瘤患者中高效抗逆转录病毒治疗与高效抗逆转录病毒治疗联合化疗的随机对照试验。
J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):150-7. doi: 10.1097/QAI.0b013e318251aedd.
5
Patient reported outcomes in routine care: advancing data capture for HIV cohort research.常规护理中的患者报告结局:推进 HIV 队列研究的数据采集。
Clin Infect Dis. 2012 Jan 1;54(1):141-7. doi: 10.1093/cid/cir727. Epub 2011 Oct 31.
6
A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).一项比较拉替拉韦和依非韦伦(SWITCH-ER 研究)的随机交叉研究。
AIDS. 2011 Jul 31;25(12):1481-7. doi: 10.1097/QAD.0b013e328348dab0.
7
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.在一项为期48周的随机研究中,关于齐多夫定/拉米夫定继续用药或换用替诺福韦酯/恩曲他滨(均联合依非韦伦)的抗逆转录病毒疗法、治疗依从性和生活质量的相关信念。
AIDS Care. 2011 Jun;23(6):705-13. doi: 10.1080/09540121.2010.534433.
8
A randomized crossover study to compare efavirenz and etravirine treatment.一项比较依非韦伦和依曲韦林治疗的随机交叉研究。
AIDS. 2011 Jan 2;25(1):57-63. doi: 10.1097/QAD.0b013e32833f9f63.
9
Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials.在DUET试验中,依曲韦林与安慰剂对经治HIV患者健康相关生活质量的影响,通过人类免疫缺陷病毒感染功能评估(FAHI)问卷进行测量。
HIV Clin Trials. 2010 Jan-Feb;11(1):18-27. doi: 10.1310/hct1101-18.
10
Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine.从病毒学有效方案转换为含依非韦伦或奈韦拉平方案后,健康相关生活质量更佳。
AIDS Care. 2010 Jan;22(1):54-61. doi: 10.1080/09540120903033250.

基于 NNRTI 的治疗方案用于 HIV 感染成人临床试验中使用的患者报告结局指标:十年回顾。

Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review.

机构信息

UBC: An Express Scripts Company, 185 Dorval Ave, Suite 500, Dorval, QC H9S 5J9, Canada.

出版信息

Health Qual Life Outcomes. 2013 Oct 3;11:164. doi: 10.1186/1477-7525-11-164.

DOI:10.1186/1477-7525-11-164
PMID:24090055
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3852266/
Abstract

BACKGROUND

Patient-reported outcomes (PROs) may provide valuable information to clinicians and patients when choosing initial antiretroviral therapy.

OBJECTIVE

To identify and classify PRO instruments used to measure treatment effects in clinical trials evaluating NNRTIs.

METHODS

We conducted a structured literature review using PubMed to identify NNRTI trials published from March 2003 to February 2013. Studies identified--based on disease, instrument, PRO, and NNRTI medication terms were reviewed--to identify PRO instruments. Domains measured within each instrument were recorded to understand key areas of interest in NNRTIs.

RESULTS

Of 189 articles reviewed, 27 validated instruments were administered in 26 unique trials, with a mean of 1.9 instruments (median: 1; range: 1-7) per trial. The Medical Outcomes Study HIV Health Survey (MOS-HIV) was the most commonly used instrument (n = 8 trials). Seventeen trials (65%) included at least one multidimensional health-related quality of life (HRQL) instrument (HIV-targeted, n = 11; general, n = 8). Other validated instruments measured sleep (n = 5), depression (n = 5), anxiety (n = 4), psychiatric symptoms (n = 2), beliefs about HIV medications (n = 2), HIV symptoms (n = 1), and stress (n = 1).

CONCLUSIONS

Although review of recent NNRTI trials suggests a lack of consensus on the optimal PRO instruments, a typical battery is comprised of a multidimensional HRQL measure coupled with one or more symptom measures. Further work is needed to clarify advantages and disadvantages of using specific PRO instruments to measure relevant constructs and to identify the most useful batteries of instruments for NNRTI trials.

摘要

背景

当选择初始抗逆转录病毒治疗时,患者报告的结局(PRO)可为临床医生和患者提供有价值的信息。

目的

确定和分类用于评估 NNRTI 临床试验中治疗效果的 PRO 工具。

方法

我们使用 PubMed 进行了一项结构化文献综述,以确定 2003 年 3 月至 2013 年 2 月期间发表的 NNRTI 试验。根据疾病、工具、PRO 和 NNRTI 药物术语对研究进行了审查,以确定 PRO 工具。记录了每个工具中测量的域,以了解 NNRTI 中的关键关注领域。

结果

在审查的 189 篇文章中,27 种经过验证的工具在 26 项独特的试验中得到了应用,平均每个试验使用 1.9 种工具(中位数:1;范围:1-7)。医疗结局研究 HIV 健康调查(MOS-HIV)是最常用的工具(n=8 项研究)。17 项试验(65%)至少包含一种多维健康相关生活质量(HRQL)工具(HIV 靶向,n=11;一般,n=8)。其他经过验证的工具测量了睡眠(n=5)、抑郁(n=5)、焦虑(n=4)、精神症状(n=2)、对 HIV 药物的信念(n=2)、HIV 症状(n=1)和压力(n=1)。

结论

尽管最近的 NNRTI 试验综述表明,在最佳 PRO 工具方面尚未达成共识,但典型的电池组由多维 HRQL 测量与一种或多种症状测量组成。需要进一步的工作来阐明使用特定 PRO 工具测量相关结构的优缺点,并确定用于 NNRTI 试验的最有用的工具电池组。